CN1338930A - 预防或降低与冠脉介入有关的心血管事件的方法 - Google Patents
预防或降低与冠脉介入有关的心血管事件的方法 Download PDFInfo
- Publication number
- CN1338930A CN1338930A CN00803386A CN00803386A CN1338930A CN 1338930 A CN1338930 A CN 1338930A CN 00803386 A CN00803386 A CN 00803386A CN 00803386 A CN00803386 A CN 00803386A CN 1338930 A CN1338930 A CN 1338930A
- Authority
- CN
- China
- Prior art keywords
- arteria coronaria
- dosage
- intervention
- ortho
- officinal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000007211 cardiovascular event Effects 0.000 title claims abstract description 36
- 230000002265 prevention Effects 0.000 title abstract description 24
- 230000009467 reduction Effects 0.000 title abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 44
- 230000003203 everyday effect Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002399 angioplasty Methods 0.000 claims description 5
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 abstract description 52
- NZHGWWWHIYHZNX-UHFFFAOYSA-N 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-UHFFFAOYSA-N 0.000 abstract 1
- 229960005342 tranilast Drugs 0.000 description 51
- 208000037803 restenosis Diseases 0.000 description 20
- 238000011160 research Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 6
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 6
- 229940127218 antiplatelet drug Drugs 0.000 description 6
- 239000000480 calcium channel blocker Substances 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- -1 brightener etc. and Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11846399P | 1999-02-03 | 1999-02-03 | |
| US60/118,463 | 1999-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1338930A true CN1338930A (zh) | 2002-03-06 |
Family
ID=22378760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00803386A Pending CN1338930A (zh) | 1999-02-03 | 2000-02-02 | 预防或降低与冠脉介入有关的心血管事件的方法 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1180027A4 (no) |
| JP (1) | JP2002536326A (no) |
| KR (1) | KR20010101933A (no) |
| CN (1) | CN1338930A (no) |
| AR (1) | AR022475A1 (no) |
| AU (1) | AU2978500A (no) |
| BR (1) | BR0007901A (no) |
| CA (1) | CA2361578A1 (no) |
| CO (1) | CO5160246A1 (no) |
| HU (1) | HUP0200148A3 (no) |
| IL (1) | IL144719A0 (no) |
| MX (1) | MXPA01007833A (no) |
| NO (1) | NO20013789L (no) |
| PL (1) | PL349926A1 (no) |
| TR (1) | TR200102262T2 (no) |
| WO (1) | WO2000045810A1 (no) |
| ZA (1) | ZA200106297B (no) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097650B2 (en) * | 2005-07-27 | 2012-01-17 | The Trustees Of Columbia University In The City Of New York | Method of treating a condition associated with phosphorylation of TASK-1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617407B2 (ja) * | 1992-09-14 | 1997-06-04 | キッセイ薬品工業株式会社 | 血管内膜細胞過剰増殖疾患の予防および治療剤 |
| WO1997009301A1 (fr) * | 1995-09-07 | 1997-03-13 | Kissei Pharmaceutical Co., Ltd. | Derives de 2-acylaminobenzamide, preventif et remede contre des maladies causees par une surmultiplication des cellules vasculaires de l'intima |
| US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
-
2000
- 2000-02-02 TR TR2001/02262T patent/TR200102262T2/xx unknown
- 2000-02-02 HU HU0200148A patent/HUP0200148A3/hu unknown
- 2000-02-02 CN CN00803386A patent/CN1338930A/zh active Pending
- 2000-02-02 KR KR1020017009743A patent/KR20010101933A/ko not_active Application Discontinuation
- 2000-02-02 EP EP00908440A patent/EP1180027A4/en not_active Withdrawn
- 2000-02-02 IL IL14471900A patent/IL144719A0/xx unknown
- 2000-02-02 MX MXPA01007833A patent/MXPA01007833A/es unknown
- 2000-02-02 BR BR0007901-4A patent/BR0007901A/pt not_active Application Discontinuation
- 2000-02-02 AR ARP000100437A patent/AR022475A1/es unknown
- 2000-02-02 WO PCT/US2000/002611 patent/WO2000045810A1/en not_active Application Discontinuation
- 2000-02-02 JP JP2000596930A patent/JP2002536326A/ja not_active Withdrawn
- 2000-02-02 AU AU29785/00A patent/AU2978500A/en not_active Abandoned
- 2000-02-02 CA CA002361578A patent/CA2361578A1/en not_active Abandoned
- 2000-02-02 PL PL00349926A patent/PL349926A1/xx not_active Application Discontinuation
- 2000-02-03 CO CO00006605A patent/CO5160246A1/es unknown
-
2001
- 2001-07-31 ZA ZA200106297A patent/ZA200106297B/en unknown
- 2001-08-02 NO NO20013789A patent/NO20013789L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01007833A (es) | 2002-06-21 |
| ZA200106297B (en) | 2002-07-31 |
| TR200102262T2 (tr) | 2002-02-21 |
| JP2002536326A (ja) | 2002-10-29 |
| IL144719A0 (en) | 2002-06-30 |
| CA2361578A1 (en) | 2000-08-10 |
| HUP0200148A2 (hu) | 2002-05-29 |
| EP1180027A1 (en) | 2002-02-20 |
| WO2000045810A1 (en) | 2000-08-10 |
| HUP0200148A3 (en) | 2003-06-30 |
| NO20013789D0 (no) | 2001-08-02 |
| CO5160246A1 (es) | 2002-05-30 |
| EP1180027A4 (en) | 2004-11-17 |
| AU2978500A (en) | 2000-08-25 |
| BR0007901A (pt) | 2001-10-30 |
| PL349926A1 (en) | 2002-10-21 |
| AR022475A1 (es) | 2002-09-04 |
| NO20013789L (no) | 2001-09-28 |
| KR20010101933A (ko) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6253734B2 (ja) | オキシブチニン治療に関連した有害な経験の最小化 | |
| WO1999040904A2 (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia | |
| CN1379686A (zh) | 含有曲马多材料和一种抗惊厥药物的组合物 | |
| JPH07330628A (ja) | 薬剤組成物及びこれを用いた治療法 | |
| JPH11510182A (ja) | セラミドのレベルを下げるための塩基性アミノ酸および誘導体の使用 | |
| Campbell et al. | Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate | |
| FR2527441A1 (fr) | Agent pour accroitre l'activite antitumorale d'un agent antitumoral et composition antitumorale le contenant | |
| CN110613726B (zh) | 核苷化合物的应用 | |
| CN1146429C (zh) | 用作抗动脉粥样硬化剂的原花色素a2的磷脂复合物 | |
| CN1092986C (zh) | 一种用于降血脂的辅酶a口服制剂及制备方法和应用 | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| CN1338930A (zh) | 预防或降低与冠脉介入有关的心血管事件的方法 | |
| WO2000043017A1 (en) | Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human | |
| CN1186336C (zh) | 秦皮总香豆素的制备方法及其在制药中的应用 | |
| CN111840512B (zh) | 治疗软骨修复和/或骨关节炎的组合物 | |
| CN1345237A (zh) | 预防或降低与冠脉介入有关的心血管事件的方法 | |
| US20030139373A1 (en) | Method for cancer therapy | |
| JP3253878B2 (ja) | 鉄キレート化用製剤、その製剤の製法及び地中海貧血症の治療法 | |
| CN1939316A (zh) | 含阿霉素的微球,其用途及其制备方法 | |
| CN1028004C (zh) | 一种类风湿病体内导向治疗剂的制造方法 | |
| CN1007959B (zh) | 经改进的抗炎组合物的制备方法 | |
| TWI756537B (zh) | 金奈米團簇於治療高膽固醇血症或與高膽固醇血症相關之疾病的用途 | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| RU2063753C1 (ru) | Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |